Cell-permeable peptide
US9023987B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 25, 2011 |
| Grant date | May 5, 2015 |
| Priority date | — |
| Expiry date | Jun 13, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof. According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immunogenicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.